Decitabine

  • Approved in 2006 by FDA for treatment of patients for with myelodysplastic syndromes (MDS), a group of diseases of the bone marrow characterized by the production of poorly functioning and immature blood cells. Over time, MDS can progress to acute leukemia, or AML
  • Generic in 2013

 

Product Description Product Code CAS Number
Decitabine D-150 2352-33-5